Literature DB >> 11711690

Duration of anticoagulation for venous thromboembolism.

C Kearon1.   

Abstract

The duration of oral anticoagulant therapy for venous thromboembolism (VTE) depends on the risk of recurrence if treatment is stopped and the risk of bleeding if treatment is continued. If the risk of recurrence is low (e.g., thrombosis provoked by a major reversible risk factor such as surgery), 3 months of treatment is usually adequate. If the risk of recurrence is high (unprovoked "idiopathic" VTE or associated with a non-reversible risk factor such as active cancer), 6 months or indefinite anticoagulant therapy is indicated. The presence of malignancy, an antiphospholipid antibody, and other selected thrombophilic states suggests more prolonged therapy, whereas isolated distal deep vein thrombosis, high risk of bleeding, and patient preference suggest a shorter course of treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711690     DOI: 10.1023/a:1012790511790

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  57 in total

1.  Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation.

Authors:  L Poller; C R Shiach; P K MacCallum; A M Johansen; A M Münster; A Magalhães; J Jespersen
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

2.  A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; A S Rhedin; P Lindmarker; A Carlsson; G Lärfars; P Nicol; E Loogna; E Svensson; B Ljungberg; H Walter
Journal:  N Engl J Med       Date:  1995-06-22       Impact factor: 91.245

3.  Clinical utility of real-time compression ultrasonography for diagnostic management of patients with recurrent venous thrombosis.

Authors:  H Heijboer; L M Jongbloets; H R Büller; A W Lensing; J W ten Cate
Journal:  Acta Radiol       Date:  1992-07       Impact factor: 1.990

4.  Minimum effective intensity of oral anticoagulant therapy in primary prevention of coronary heart disease.

Authors:  P K MacCallum; P J Brennan; T W Meade
Journal:  Arch Intern Med       Date:  2000-09-11

5.  Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.

Authors:  J D Douketis; G A Foster; M A Crowther; M H Prins; J S Ginsberg
Journal:  Arch Intern Med       Date:  2000 Dec 11-25

6.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

7.  Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism.

Authors:  P M Kuijer; B A Hutten; M H Prins; H R Büller
Journal:  Arch Intern Med       Date:  1999-03-08

8.  Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.

Authors:  R J Beyth; L M Quinn; C S Landefeld
Journal:  Am J Med       Date:  1998-08       Impact factor: 4.965

Review 9.  Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.

Authors:  C S Landefeld; R J Beyth
Journal:  Am J Med       Date:  1993-09       Impact factor: 4.965

Review 10.  Venous thrombosis: a multicausal disease.

Authors:  F R Rosendaal
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

View more
  1 in total

1.  Clinical relevance of chronic respiratory disease in Korean patients with pulmonary thromboembolism.

Authors:  Hyeyoung Park; Seung-Ick Cha; Jae-Kwang Lim; Kyung-Min Shin; Yong-Hoon Lee; Hyewon Seo; Seung-Soo Yoo; Shin-Yup Lee; Jaehee Lee; Chang-Ho Kim; Jae-Yong Park
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.